CAMP4 Therapeutics Corporation (CAMP) – What Are Investment Firms Thinking About This Stock?

Posted by Francis Steltz on Nov 1st, 2026

Shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the eleven brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $10.44.

A number of research firms have commented on CAMP. Raymond James Financial assumed coverage on CAMP4 Therapeutics in a report on Friday, October 23rd. They set a “strong-buy” rating and a $10.00 price target on the stock. Needham & Company LLC initiated coverage on CAMP4 Therapeutics in a research note on Thursday, October 15th. They set a “buy” rating and a $8.00 price target for the company. Oppenheimer began coverage on CAMP4 Therapeutics in a research note on Monday, October 5th. They issued an “outperform” rating and a $15.00 price objective on the stock. Weiss Ratings raised shares of CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 16th. Finally, Chardan Capital dropped their target price on CAMP4 Therapeutics from $6.50 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, September 29th.

Get Our Latest Stock Report on CAMP4 Therapeutics

Insiders Place Their Bets

In other news, Director Richard A. Young purchased 16,378 shares of the stock in a transaction dated Monday, August 3rd. The shares were acquired at an average cost of $1.65 per share, for a total transaction of $27,023.70. Following the acquisition, the director owned 186,388 shares of the company’s stock, valued at approximately $307,540.20. This represents a 9.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Kelly Gold acquired 10,000 shares of the firm’s stock in a transaction dated Monday, August 31st. The shares were acquired at an average price of $3.96 per share, with a total value of $39,600.00. Following the acquisition, the chief financial officer owned 10,000 shares in the company, valued at approximately $39,600. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders bought 46,031 shares of company stock worth $99,051 and sold 593,613 shares worth $2,504,037. Company insiders own 21.69% of the company’s stock.

Institutional Trading of CAMP4 Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE purchased a new stake in CAMP4 Therapeutics during the second quarter worth $78,000. Trails Edge Capital Partners LP purchased a new position in shares of CAMP4 Therapeutics during the 2nd quarter valued at approximately $8,446,935. Jupiter Topco LLC acquired a new stake in CAMP4 Therapeutics in the 2nd quarter valued at $27,581,000. 5AM Venture Management LLC acquired a new position in CAMP4 Therapeutics during the second quarter worth $25,647,928. Finally, BlackRock Inc. purchased a new stake in shares of CAMP4 Therapeutics during the second quarter worth about $7,185,000.

CAMP4 Therapeutics Stock Up 1.5%

NASDAQ:CAMP opened at $3.96 on Friday. The company has a fifty day moving average of $3.89 and a 200 day moving average of $4.24. The firm has a market capitalization of $248.49 million, a P/E ratio of -1.71 and a beta of 0.27. CAMP4 Therapeutics has a 52 week low of $2.90 and a 52 week high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) last announced its earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). The business had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. As a group, analysts anticipate that CAMP4 Therapeutics will post -0.68 EPS for the current year.

CAMP4 Therapeutics Company Profile

(Get Free Report)

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing medicines that increase the production of disease-relevant proteins by activating the expression of specific genes. The company’s approach is designed to address diseases caused by insufficient protein levels, including certain genetic disorders in which boosting activity from a functional gene copy may provide therapeutic benefit.

CAMP4 uses its Regulatory Action Platform, or RAP, to identify regulatory elements that control RNA production and discover small-molecule compounds capable of increasing the expression of selected genes.